-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Downgrades Iovance Biotherapeutics to Neutral, Lowers Price Target to $2

Benzinga·05/16/2025 11:18:30
Listen to the news
UBS analyst David Dai downgrades Iovance Biotherapeutics (NASDAQ:IOVA) from Buy to Neutral and lowers the price target from $17 to $2.